albuterol (Ventolin) vs Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol (Ventolin)
Marketed by GlaxoSmithKline
NCT00144846 · Phase 3 · completed
Although the registry describes 80 participants as randomized and double-blind, it lists only a single albuterol arm with no placebo or active comparator. The primary endpoint was safety, and no results are posted, so the study cannot provide a controlled comparison of treatment benefit.
Next expected readout: April 2027 · NCT06433921 (registry estimate)
No aligned efficacy figure on record for this race.
Vilanterol
Developed by GlaxoSmithKline
NCT00381667 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, but enrolled only 14 participants. Its primary outcomes included lung-function and safety measurements rather than a hard clinical endpoint, and the primary comparison cannot be assessed because results have not been posted.
Reported efficacy
Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036) (mixed)
Result source: NCT00600171
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | albuterol (Ventolin) | Vilanterol |
|---|---|---|
| Severe exacerbations, annualised rate | —Not posted · NCT06657066 | —Not reported |
| Trough FEV1, change | 0.1 vs 0.0vs ADVAIR DISKUSNCT0217577114 other results
| 0.3 vs 0.1+0.1 vs placeboNCT006001718 other results
|
| ACQ-5, change | —Not posted · NCT06657066 | —Not reported |
| OCS dose reduction | —Not posted · NCT06657066 | —Not reported |
Severe exacerbations, annualised rate
- albuterol (Ventolin)
- —Not posted · NCT06657066
- Vilanterol
- —Not reported
Trough FEV1, change
- albuterol (Ventolin)
- 0.1 vs 0.0vs ADVAIR DISKUSNCT02175771
14 other results
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.0 NCT02175771
- 0.3 vs 0.1 NCT01479621
- 0.2 vs 0.1 NCT01479621
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.2 vs 0.1 NCT01479621
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.2 vs 0.1 NCT01479621
- Vilanterol
- 0.3 vs 0.1+0.1 vs placeboNCT00600171
8 other results
- 0.3 vs 0.1 NCT00600171
- 0.3 vs 0.1 NCT00600171
- 0.2 vs 0.1 NCT00600171
- 0.2 vs 0.1 NCT00600171
- -0.5 vs -0.8 NCT01128569
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
ACQ-5, change
- albuterol (Ventolin)
- —Not posted · NCT06657066
- Vilanterol
- —Not reported
OCS dose reduction
- albuterol (Ventolin)
- —Not posted · NCT06657066
- Vilanterol
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. albuterol (Ventolin): 7 of 7 rows · Vilanterol: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | albuterol (Ventolin) Rows use multiple source trials | Vilanterol Rows use multiple source trials |
|---|---|---|
| FEV1 absolute change · L | 5.96 vs -1.38 placebo La,b,c,d,e NCT05087693 · Phase 4 · registry result, not featured evidence show 1 more dose6.98 vs -1.38 placebo L NCT05087693 · Phase 4 · registry result, not featured evidence | -0.227 vs -0.372 placebo L @ 4.14wk100/25 µg ODb,c,d,e NCT01128569 · Phase 2 · registry result, not featured evidence |
| FEV1 Wm0 24 h absolute change · L | 0.048 vs -0.025 placebo L @ 2wk250 µg QDa,c,d NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 show 6 more doses0.094 vs -0.025 placebo L @ 2wk125 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0.092 vs -0.025 placebo L @ 2wk62.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0.043 vs -0.025 placebo L @ 2wk31.25 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0.077 vs -0.025 placebo L @ 2wk31.25 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0.097 vs -0.025 placebo L @ 2wk15.6 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0.06 vs -0.025 placebo L @ 2wk15.6 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 | 3.188 vs 2.811 placebo L @ 2wk100/25 µg AMa,c,d NCT01287065 · Phase 2 · registry result, not featured evidence show 1 more dose3.233 vs 2.811 placebo L @ 2wk100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence |
| Rescue-free 24-h Period percent change · % of baseline | 24.07% (n=102) vs 21.3% (n=102) placebo @ 12wk100 mcga,f,c,d NCT01479621 · Phase 2 · registry result, not featured evidence show 3 more doses28.06% (n=102) vs 21.3% (n=102) placebo @ 12wk50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 31.76% (n=101) vs 21.3% (n=102) placebo @ 12wk25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 34.08% (n=102) vs 21.3% (n=102) placebo @ 12wk12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence | 21.7% (n=115) vs 14.6% (n=115) placebo @ 12wk25 µg ODf,c,d NCT01181895 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 10%100 mg SCg NCT04276233 · Phase 4 · registry result, not featured evidence show 38 more results—Exercising in Filtered Air Followi NCT05087693 · Phase 4 · registry result, not featured evidence —Exercising in Ozone Following Salb NCT05087693 · Phase 4 · registry result, not featured evidence 16.7% NCT03924635 · Phase 4 · registry result, not featured evidence · combination 4.8%100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence — NCT01471340 · Phase 4 · registry result, not featured evidence · pooled 7.7%50/250 mcg NCT00363480 · Phase 4 · registry result, not featured evidence 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 11.1%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 7.3%200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 2.2%100/10 mcg BID NCT02741271 · Phase 3 · registry result, not featured evidence — NCT02502734 · Phase 3 · registry result, not featured evidence —200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5.7% NCT01687296 · Phase 3 · registry result, not featured evidence 12.6%200 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 16%100 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 18.5%160 µg NCT00384189 · Phase 3 · registry result, not featured evidence 18.3%80 µg NCT00384189 · Phase 3 · registry result, not featured evidence 16.4%40 µg NCT00384189 · Phase 3 · registry result, not featured evidence —800 μg NCT02479412 · Phase 2 · registry result, not featured evidence —250 μg NCT02479412 · Phase 2 · registry result, not featured evidence —58 μg NCT02479412 · Phase 2 · registry result, not featured evidence —100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 5.1%250 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 9.3%125 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 5.9%31.25 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 2%31.25 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —200 ug NCT06433908 · Phase 1 · registry result, not featured evidence —800 ug NCT06433908 · Phase 1 · registry result, not featured evidence | 7.9%25 µgh NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results4.9%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 9.9%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 16.8%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12.2%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence 21.1%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 12.4%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 18.4%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —25 µg NCT01453296 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 1%100 mg SCg NCT04276233 · Phase 4 · registry result, not featured evidence show 38 more results—Exercising in Filtered Air Followi NCT05087693 · Phase 4 · registry result, not featured evidence —Exercising in Ozone Following Salb NCT05087693 · Phase 4 · registry result, not featured evidence — NCT03924635 · Phase 4 · registry result, not featured evidence · combination —100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence — NCT01471340 · Phase 4 · registry result, not featured evidence · pooled 1.8%50/250 mcg NCT00363480 · Phase 4 · registry result, not featured evidence 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 1.8%200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence —100/10 mcg BID NCT02741271 · Phase 3 · registry result, not featured evidence — NCT02502734 · Phase 3 · registry result, not featured evidence —200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence — NCT01687296 · Phase 3 · registry result, not featured evidence 1.7%200 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 1.7%100 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence —160 µg NCT00384189 · Phase 3 · registry result, not featured evidence —80 µg NCT00384189 · Phase 3 · registry result, not featured evidence —40 µg NCT00384189 · Phase 3 · registry result, not featured evidence —800 μg NCT02479412 · Phase 2 · registry result, not featured evidence —250 μg NCT02479412 · Phase 2 · registry result, not featured evidence —58 μg NCT02479412 · Phase 2 · registry result, not featured evidence —100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%250 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%31.25 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —200 ug NCT06433908 · Phase 1 · registry result, not featured evidence —800 ug NCT06433908 · Phase 1 · registry result, not featured evidence | 1%25 µgh NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results0%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 1%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0.9%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence 0.9%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —25 µg NCT01453296 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 3%100 mg SCg NCT04276233 · Phase 4 · registry result, not featured evidence show 38 more results0%Exercising in Filtered Air Followi NCT05087693 · Phase 4 · registry result, not featured evidence 0%Exercising in Ozone Following Salb NCT05087693 · Phase 4 · registry result, not featured evidence 4.2% NCT03924635 · Phase 4 · registry result, not featured evidence · combination 11%100 mg SC NCT02654145 · Phase 4 · registry result, not featured evidence 2.3% NCT01471340 · Phase 4 · registry result, not featured evidence · pooled 0.5%50/250 mcg NCT00363480 · Phase 4 · registry result, not featured evidence 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 3.6%200/62.5/25 mcg NCT03184987 · Phase 3 · registry result, not featured evidence 1.1%100/10 mcg BID NCT02741271 · Phase 3 · registry result, not featured evidence 0% NCT02502734 · Phase 3 · registry result, not featured evidence 9.8%200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 6.4%200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5%100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5.5%100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 0.8% NCT01687296 · Phase 3 · registry result, not featured evidence 3.4%200 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 2.5%100 µg OD NCT01431950 · Phase 3 · registry result, not featured evidence 0.6%160 µg NCT00384189 · Phase 3 · registry result, not featured evidence 1.6%80 µg NCT00384189 · Phase 3 · registry result, not featured evidence 1.3%40 µg NCT00384189 · Phase 3 · registry result, not featured evidence 0%800 μg NCT02479412 · Phase 2 · registry result, not featured evidence 0%250 μg NCT02479412 · Phase 2 · registry result, not featured evidence 0%58 μg NCT02479412 · Phase 2 · registry result, not featured evidence 1.9%100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 1%50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0.7%250 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%31.5 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 —31.25 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 3.3%200 ug NCT06433908 · Phase 1 · registry result, not featured evidence 0%800 ug NCT06433908 · Phase 1 · registry result, not featured evidence | 0%25 µgh NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results0%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0.9%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence —25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence 0%100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence 0%25 µg NCT01453296 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 100 mg SCg pyrexia 5% headache 3% oropharyngeal pain 3% NCT04276233 · Phase 4 · registry result, not featured evidence show 34 more results100 mg SC headache 28.3% viral upper respiratory tract infection 16.6% bronchitis 13.1% NCT02654145 · Phase 4 · registry result, not featured evidence asthma 0.1% dry mouth 0.1% dysphonia 0.1% NCT01471340 · Phase 4 · registry result, not featured evidence · pooled 50/250 mcg headache 10.4% nasopharyngitis 8.1% bronchitis 5.4% NCT00363480 · Phase 4 · registry result, not featured evidence 100/62.5/25 mcg nasopharyngitis 27.7% pharyngitis 10.6% bronchitis 8.5% NCT03184987 · Phase 3 · registry result, not featured evidence 100/62.5/25 mcg to 200/62.5/25 mcg bronchitis 22.2% dysgeusia 22.2% nasopharyngitis 22.2% NCT03184987 · Phase 3 · registry result, not featured evidence 200/62.5/25 mcg nasopharyngitis 32.7% dysgeusia 10.9% eczema 9.1% NCT03184987 · Phase 3 · registry result, not featured evidence 100/10 mcg BID asthma 11% upper respiratory tract infection 9.9% influenza 5.5% NCT02741271 · Phase 3 · registry result, not featured evidence nasopharyngitis 6.9% (placebo 8.3%) headache 5.2% (placebo 13.3%) cough 3.4% (placebo 5%) NCT02502734 · Phase 3 · registry result, not featured evidence 200/12.5 mcg upper respiratory tract infection 18% sinusitis 10.5% nasopharyngitis 9% NCT02175771 · Phase 3 · registry result, not featured evidence 200 mcg upper respiratory tract infection 13.6% cough 10.4% nasopharyngitis 10.4% NCT02175771 · Phase 3 · registry result, not featured evidence 100/12.5 mcg upper respiratory tract infection 17.5% nasopharyngitis 12.5% cough 11.7% NCT02175771 · Phase 3 · registry result, not featured evidence 100 mcg upper respiratory tract infection 18.1% nasopharyngitis 13.4% sinusitis 11.8% NCT02175771 · Phase 3 · registry result, not featured evidence white blood cell count increased 0.8% NCT01687296 · Phase 3 · registry result, not featured evidence 200 µg OD headache 12.6% nasopharyngitis 12.6% bronchitis 6.7% NCT01431950 · Phase 3 · registry result, not featured evidence 100 µg OD bronchitis 11.8% nasopharyngitis 11.8% headache 10.1% NCT01431950 · Phase 3 · registry result, not featured evidence 160 µg pharyngitis 5.2% (placebo 4.8%) upper respiratory tract infection 5.2% (placebo 3.4%) nasopharyngitis 4.2% (placebo 2.1%) NCT00384189 · Phase 3 · registry result, not featured evidence 80 µg upper respiratory tract infection 6.4% (placebo 3.4%) pharyngitis 5.8% (placebo 4.8%) nasopharyngitis 3.2% (placebo 2.1%) NCT00384189 · Phase 3 · registry result, not featured evidence 40 µg nasopharyngitis 6.2% (placebo 2.1%) upper respiratory tract infection 5.9% (placebo 3.4%) pharyngitis 4.6% (placebo 4.8%) NCT00384189 · Phase 3 · registry result, not featured evidence 800 μg nasopharyngitis 11.8% (placebo 15.4%) diarrhoea 8.8% (placebo 0%) headache 5.9% (placebo 0%) NCT02479412 · Phase 2 · registry result, not featured evidence 250 μg headache 8.8% (placebo 0%) nasopharyngitis 5.9% (placebo 15.4%) asthma 2.9% (placebo 1.9%) NCT02479412 · Phase 2 · registry result, not featured evidence 58 μg nasopharyngitis 11.8% (placebo 15.4%) gastroenteritis 8.8% (placebo 0%) cough 5.9% (placebo 1.9%) NCT02479412 · Phase 2 · registry result, not featured evidence 100 mcg upper respiratory tract infection 4.9% (placebo 2.9%) nasopharyngitis 2.9% (placebo 4.8%) NCT01479621 · Phase 2 · registry result, not featured evidence 50 mcg nasopharyngitis 6.7% (placebo 4.8%) upper respiratory tract infection 2.9% (placebo 2.9%) NCT01479621 · Phase 2 · registry result, not featured evidence 25 mcg nasopharyngitis 4.8% (placebo 4.8%) upper respiratory tract infection 1.9% (placebo 2.9%) NCT01479621 · Phase 2 · registry result, not featured evidence 12.5 mcg upper respiratory tract infection 6.8% (placebo 2.9%) nasopharyngitis 3.9% (placebo 4.8%) NCT01479621 · Phase 2 · registry result, not featured evidence 250 µg QD headache 4.4% (placebo 1.6%) product taste abnormal 3.7% (placebo 0%) nasopharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 125 µg QD headache 3.1% (placebo 1.6%) product taste abnormal 3.1% (placebo 0%) nasopharyngitis 2.3% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 62.5 µg QD headache 3.8% (placebo 1.6%) pharyngitis 3.8% (placebo 0.8%) nasopharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 31.5 µg QD headache 2.9% (placebo 1.6%) product taste abnormal 1.4% (placebo 0%) pharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 31.25 µg BID headache 4.5% (placebo 1.6%) nasopharyngitis 1.5% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 15.6 µg BID nasopharyngitis 3.2% (placebo 0.8%) headache 1.6% (placebo 1.6%) pharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 15.6 µg QD headache 3.8% (placebo 1.6%) nasopharyngitis 2.3% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 200 ug catheter site haematoma 16.7% headache 10% abdominal pain 6.7% NCT06433908 · Phase 1 · registry result, not featured evidence 800 ug catheter site related reaction 30% headache 16.7% cough 10% NCT06433908 · Phase 1 · registry result, not featured evidence | 25 µgh headache 6.9% (placebo 7.8%) upper respiratory tract infection 2% (placebo 2%) nasopharyngitis 0% (placebo 3.9%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 13 more results50 µg headache 7.8% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 2% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12.5 µg headache 9% (placebo 7.8%) upper respiratory tract infection 3% (placebo 2%) nasopharyngitis 0% (placebo 3.9%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 6.25 µg headache 6.9% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 1% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 3 µg headache 11.9% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 2% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 25 µg OD headache 8.7% (placebo 4.3%) nasopharyngitis 7.8% (placebo 10.3%) oropharyngeal pain 5.2% (placebo 6%) NCT01181895 · Phase 3 · registry result, not featured evidence 12.5 OD nasopharyngitis 8.8% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 25 OD nasopharyngitis 7.9% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 6.25 OD nasopharyngitis 7% (placebo 7%) headache 5.3% (placebo 3.5%) influenza 3.5% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 100/25 µg AM headache 25% (placebo 26.1%) nasopharyngitis 12.5% (placebo 13%) dysmenorrhoea 4.2% (placebo 0%) NCT01287065 · Phase 2 · registry result, not featured evidence 100/25 µg PM headache 32% (placebo 26.1%) gastroenteritis 8% (placebo 0%) nasopharyngitis 8% (placebo 13%) NCT01287065 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 55.6% (placebo 40.7%) nasopharyngitis 11.1% (placebo 7.4%) oropharyngeal pain 11.1% (placebo 7.4%) NCT01128595 · Phase 2 · registry result, not featured evidence 25 µg upper respiratory tract infection 11.1% (placebo 0%) headache 7.4% (placebo 7.7%) pyrexia 7.4% (placebo 0%) NCT01453296 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 9.8% (placebo 17.6%) dysphonia 3.9% (placebo 0%) mouth ulceration 3.9% (placebo 0%) NCT01128569 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 2 versus Phase 4.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eThe assessment timepoint is not available for both results.
- fTrial phases differ: Phase 3 versus Phase 2.
- gPopulation comparability has not been reviewed for 31 of these studies.
- hPopulation comparability has not been reviewed for 12 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
albuterol (Ventolin)
show 1 more result
show 6 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 37 further endpoints in the CSV export.
Vilanterol
show 9 more results
show 5 more results
show 5 more results
show 4 more results
show 4 more results
show 3 more results
show 5 more results
show 5 more results
show 1 more result
show 1 more result
+ 5 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol (Ventolin)'s landscape · Vilanterol's landscape